Q3 2025 Earnings Call Transcript November 13, 2025 TriSalus Life Sciences, Inc. misses on earnings expectations. Reported EPS is $-0.96 EPS, expectations were $-0.17. Operator: Good afternoon, and ...
IR uses the blood vessel network in the body as almost like a subway map. We can get on and off at different stops to access different parts of the body and treat disease. IR is the intersection of ...
4don MSN
TriSalus reaffirms 50% revenue growth target while advancing TriNav platform and product launches
Discover TriSalus Life Sciences' Q3 2025 earnings: 57% revenue growth, new product launches, and a reaffirmed 50% growth outlook.
News-Medical.Net on MSN
Understanding thrombocytopenia in patients with portal hypertension and chronic liver disease
Chronic liver disease (CLD) and its advanced stage, cirrhosis, represent a significant global health burden, with portal ...
The global interventional oncology market size is expected to reach USD 4.38 billion by 2030, registering a CAGR of 8.55% ...
TriSalus Life Sciences Inc (TLSI) reports a 57% revenue increase, expands its product portfolio, and navigates challenges in manufacturing and reimbursement.
A new Cedars-Sinai Cancer study shows that patients with advanced liver cancer who receive immunotherapy to shrink their ...
A local teen faced a sudden medical crisis that changed everything overnight. Now, she’s taking her first steps toward ...
A Connecticut woman was suffering stomach pains when a colonoscopy revealed she had advanced colorectal cancer that had spread to her liver,<a class="excerpt-read-more" href=" More ...
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback